MétaCan
Menu
Back to cohort
Record W4396508551 · doi:10.1002/cncr.35301

Langerhans cell histiocytosis: NACHO update on progress, chaos, and opportunity on the path to rational cures

2024· review· en· W4396508551 on OpenAlexaff
Kevin Bielamowicz, Peter Dimitrion, Oussama Abla, Simon Bomken, Patrick Campbell, Matthew Collin, Barbara Degar, Eli L. Diamond, Olive S. Eckstein, Nader Kim El‐Mallawany, Mark Fluchel, Gaurav Goyal, M M Henry, Michelle L. Hermiston, Michael D. Hogarty, Michael Jeng, Rima Jubran, Joseph Lubega, Ashish Kumar, Stephan Ladisch, Kenneth L. McClain, Miriam Mérad, Qing‐Sheng Mi, D. Williams Parsons, Erin C. Peckham‐Gregory, Jennifer Picarsic, Zachary D. Prudowsky, Barrett J. Rollins, Peter H. Shaw, Birte Wistinghausen, Carlos Rodríguez‐Galindo, Carl E. Allen

Bibliographic record

VenueCancer · 2024
Typereview
Languageen
FieldMedicine
TopicHistiocytic Disorders and Treatments
Canadian institutionsHospital for Sick Children
FundersNational Center for Advancing Translational SciencesNational Institutes of HealthNational Cancer InstituteApplebaum FoundationEunice Kennedy Shriver National Institute of Child Health and Human DevelopmentSt. Baldrick's FoundationLeukemia and Lymphoma Society
KeywordsMedicineLangerhans cell histiocytosisDiseaseClinical trialHistiocyteHistiocytosisMyeloidImmunologyPathology

Abstract

fetched live from OpenAlex

Langerhans cell histiocytosis (LCH) is a myeloid neoplastic disorder characterized by lesions with CD1a-positive/Langerin (CD207)-positive histiocytes and inflammatory infiltrate that can cause local tissue damage and systemic inflammation. Clinical presentations range from single lesions with minimal impact to life-threatening disseminated disease. Therapy for systemic LCH has been established through serial trials empirically testing different chemotherapy agents and durations of therapy. However, fewer than 50% of patients who have disseminated disease are cured with the current standard-of-care vinblastine/prednisone/(mercaptopurine), and treatment failure is associated with long-term morbidity, including the risk of LCH-associated neurodegeneration. Historically, the nature of LCH-whether a reactive condition versus a neoplastic/malignant condition-was uncertain. Over the past 15 years, seminal discoveries have broadly defined LCH pathogenesis; specifically, activating mitogen-activated protein kinase pathway mutations (most frequently, BRAFV600E) in myeloid precursors drive lesion formation. LCH therefore is a clonal neoplastic disorder, although secondary inflammatory features contribute to the disease. These paradigm-changing insights offer a promise of rational cures for patients based on individual mutations, clonal reservoirs, and extent of disease. However, the pace of clinical trial development behind lags the kinetics of translational discovery. In this review, the authors discuss the current understanding of LCH biology, clinical characteristics, therapeutic strategies, and opportunities to improve outcomes for every patient through coordinated agent prioritization and clinical trial efforts.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.697
Threshold uncertainty score0.647

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.078
GPT teacher head0.377
Teacher spread0.299 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations26
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueCancerSame topicHistiocytic Disorders and TreatmentsFrench-language works237,207